A Study Comparing BL-B01D1 With the Investigator's Choice of Chemotherapy in Patients With Platinum-resistant Recurrent Epithelial Ovarian Cancer
- Conditions
- Epithelial Ovarian CancerFallopian Tube CancerPrimary Peritoneal Cancer
- Interventions
- Drug: Liposomal doxorubicin, Paclitaxel or Topotecan
- First Posted Date
- 2025-05-29
- Last Posted Date
- 2025-05-29
- Lead Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
- Target Recruit Count
- 540
- Registration Number
- NCT06994195
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
A Study of BL-B01D1 Combined With Lenvatinib in Patients With Advanced Hepatocellular Carcinoma
- Conditions
- Advanced Hepatocellular Carcinoma
- Interventions
- First Posted Date
- 2025-05-23
- Last Posted Date
- 2025-05-23
- Lead Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
- Target Recruit Count
- 46
- Registration Number
- NCT06986785
- Locations
- 🇨🇳
Zhongshan Hospital Fudan University, Shanghai, Shanghai, China
A Study of BL-B01D1+PD-1/PD-L1 Monoclonal Antibody in Patients With Advanced Biliary Tract Cancer
- Conditions
- Advanced Biliary Tract Cancer
- Interventions
- First Posted Date
- 2025-05-18
- Last Posted Date
- 2025-07-02
- Lead Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
- Target Recruit Count
- 46
- Registration Number
- NCT06978114
- Locations
- 🇨🇳
Zhongshan Hospital Fudan University, Shanghai, Shanghai, China
A Study of BL-B01D1 + Axitinib Without or With Pembrolizumab in Patients With Locally Advanced or Metastatic Renal Cancer
- Conditions
- Renal Cancer
- Interventions
- First Posted Date
- 2025-05-08
- Last Posted Date
- 2025-05-08
- Lead Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
- Target Recruit Count
- 120
- Registration Number
- NCT06962787
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
A Study of BL-M07D1 Versus Investigator's Choice of Chemotherapy in Patients With HER2-low Recurrent/Metastatic Breast Cancer
- Conditions
- HER2-low Breast Cancer
- Interventions
- Drug: Capecitabine, Eribulin, Gemcitabine, Paclitaxel, or Albumin paclitaxel
- First Posted Date
- 2025-05-06
- Last Posted Date
- 2025-05-30
- Lead Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
- Target Recruit Count
- 564
- Registration Number
- NCT06957886
- Locations
- 🇨🇳
Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, Guangdong, China
🇨🇳Hunan Cancer Hospital, Changsha, Hunan, China
A Study of BL-M09D1 in Patients With Locally Advanced or Metastatic Gastrointestinal Tumors and Other Solid Tumors
- First Posted Date
- 2025-05-01
- Last Posted Date
- 2025-05-31
- Lead Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
- Target Recruit Count
- 45
- Registration Number
- NCT06954077
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
A Study of BL-M07D1 + Pertuzumab With or Without Taxane Versus Taxane + Trastuzumab and Pertuzumab in Neoadjuvant Therapy for HER2-Positive Breast Cancer
- Conditions
- HER2-positive Breast Cancer
- Interventions
- First Posted Date
- 2025-03-24
- Last Posted Date
- 2025-06-15
- Lead Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
- Target Recruit Count
- 120
- Registration Number
- NCT06891833
- Locations
- 🇨🇳
The First Affiliated Hospital of Bengbu Medical University, Bengbu, Anhui, China
🇨🇳Anhui Provincial Cancer Hospital, Hefei, Anhui, China
🇨🇳The First Affiliated Hospital of University of Science and Technology of China (Anhui Provincial Hospital), Hefei, Anhui, China
A Study of GNC-038 Tetra-specific Antibody Injection in Patients With Rheumatoid Arthritis
- First Posted Date
- 2025-03-04
- Last Posted Date
- 2025-04-15
- Lead Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
- Target Recruit Count
- 54
- Registration Number
- NCT06857227
- Locations
- 🇨🇳
Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, Shanghai, China
A Study of GNC-038 Tetra-specific Antibody Injection in Patients With Systemic Lupus Erythematosus
- First Posted Date
- 2025-03-04
- Last Posted Date
- 2025-06-24
- Lead Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
- Target Recruit Count
- 54
- Registration Number
- NCT06857214
- Locations
- 🇨🇳
Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, Shanghai, China
A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Recurrent or Metastatic Urothelial Carcinoma
- Conditions
- Urothelial Carcinoma
- Interventions
- First Posted Date
- 2025-03-04
- Last Posted Date
- 2025-05-02
- Lead Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
- Target Recruit Count
- 674
- Registration Number
- NCT06857175
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China